Traws Pharma (NASDAQ:TRAW) Posts Quarterly Earnings Results, Beats Expectations By $0.03 EPS

by · The Cerbat Gem

Traws Pharma (NASDAQ:TRAW – Get Free Report) released its quarterly earnings results on Friday. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.03, FiscalAI reports.

Traws Pharma Stock Up 15.3%

TRAW stock traded up $0.25 during midday trading on Friday, reaching $1.88. 1,927,070 shares of the company’s stock traded hands, compared to its average volume of 1,508,600. The company has a 50-day simple moving average of $1.68 and a two-hundred day simple moving average of $1.86. Traws Pharma has a 1-year low of $0.99 and a 1-year high of $3.27. The company has a market cap of $19.10 million, a price-to-earnings ratio of 2.03 and a beta of 1.47.

Insiders Place Their Bets

In other Traws Pharma news, major shareholder Orbimed Advisors Llc purchased 597,729 shares of the company’s stock in a transaction that occurred on Thursday, April 16th. The stock was purchased at an average cost of $1.67 per share, with a total value of $998,207.43. Following the acquisition, the insider directly owned 1,203,250 shares of the company’s stock, valued at approximately $2,009,427.50. This trade represents a 98.71% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. 14.00% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Traws Pharma

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Adage Capital Partners GP L.L.C. increased its holdings in Traws Pharma by 121.2% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 730,000 shares of the company’s stock valued at $825,000 after purchasing an additional 400,000 shares in the last quarter. Squadron Capital Management LLC bought a new position in Traws Pharma in the 4th quarter valued at $806,000. Ikarian Capital LLC boosted its position in Traws Pharma by 2,280.0% in the 4th quarter. Ikarian Capital LLC now owns 678,142 shares of the company’s stock valued at $766,000 after buying an additional 649,649 shares during the last quarter. Boothbay Fund Management LLC bought a new position in Traws Pharma in the 4th quarter valued at $220,000. Finally, ADAR1 Capital Management LLC bought a new position in Traws Pharma in the 4th quarter valued at $175,000. 7.95% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Weiss Ratings upgraded Traws Pharma from a “sell (d-)” rating to a “sell (d+)” rating in a research note on Friday, May 1st. LADENBURG THALM/SH SH raised Traws Pharma to a “strong-buy” rating in a report on Friday, January 30th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $8.00.

View Our Latest Research Report on Traws Pharma

Traws Pharma Company Profile

(Get Free Report)

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.

Recommended Stories